StockDrifts LogoStockDrifts

Siren L L C 13F Portfolio

Portfolio Manager
Siren L L C
Performance
+26.39% (2026 Q2)
AUM (13F)
$4.94B
# of Holdings
115
Performance Rank
N/A
Allocation (Top 20)
62.17%
Latest filing
Q2 2026

Siren L L C Holdings Map

Top 50 Siren L L C Holdings

Top 10 holdings

StockCompany% Port.SharesValueActivityOwnershipAvg. CostDate
SRRK
Scholar Rock Holding Corp
10.69%9.58M$526.6M
-11.55%(-1.25M)
2025-Q2: 9.25M shares2025-Q3: 9.25M shares2025-Q4: 10.83M shares2026-Q1: 10.83M shares2026-Q2: 9.58M shares
$12.90(+319.00%)
2026-06-30
KYMR
Kymera Therapeutics Inc
6.83%2.94M$336.7M
-7.88%(-251.00K)
2025-Q2: 3.43M shares2025-Q3: 3.43M shares2025-Q4: 3.29M shares2026-Q1: 3.19M shares2026-Q2: 2.94M shares
$38.10(+195.24%)
2026-06-30
ERAS
Erasca Inc
4.24%11.40M$208.8M
+1.37%(+153.53K)
2025-Q2: 8.76M shares2025-Q3: 8.76M shares2025-Q4: 8.76M shares2026-Q1: 11.24M shares2026-Q2: 11.40M shares
$4.35(+327.08%)
2026-06-30
MANE
Veradermics Inc
4.13%1.66M$203.5M
+9.96%(+150.00K)
2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 0 shares2026-Q1: 1.51M shares2026-Q2: 1.66M shares
$65.75(+64.13%)
2026-06-30
TNGX
Tango Therapeutics Inc
3.92%6.18M$193.2M
+9.23%(+522.26K)
2025-Q2: 3.36M shares2025-Q3: 5.88M shares2025-Q4: 8.17M shares2026-Q1: 5.66M shares2026-Q2: 6.18M shares
$8.89(+187.86%)
2026-06-30
RVMD
Revolution Medicines Inc
3.42%900.0K$168.6M
-18.99%(-210.98K)
2025-Q2: 938.8K shares2025-Q3: 1.04M shares2025-Q4: 1.34M shares2026-Q1: 1.11M shares2026-Q2: 900.0K shares
$45.25(+353.61%)
2026-06-30
BCAX
Bicara Therapeutics Inc
3.38%5.60M$166.4M
-3.45%(-200.00K)
2025-Q2: 5.22M shares2025-Q3: 5.22M shares2025-Q4: 5.22M shares2026-Q1: 5.80M shares2026-Q2: 5.60M shares
$19.87(+23.27%)
2026-06-30
ARWR
Arrowhead Pharmaceuticals Inc
2.84%1.72M$139.8M
+6.19%(+100.00K)
2025-Q2: 2.67M shares2025-Q3: 2.67M shares2025-Q4: 1.50M shares2026-Q1: 1.62M shares2026-Q2: 1.72M shares
$27.74(+214.52%)
2026-06-30
ONC
BeOne Medicines AG
2.69%465.0K$132.5M
+0.00%(+0)
2025-Q2: 510.0K shares2025-Q3: 493.0K shares2025-Q4: 500.0K shares2026-Q1: 465.0K shares2026-Q2: 465.0K shares
$189.89(+88.33%)
2026-06-30
EWTX
Edgewise Therapeutics Inc
2.63%3.18M$129.4M
-28.12%(-1.25M)
2025-Q2: 3.16M shares2025-Q3: 3.90M shares2025-Q4: 4.53M shares2026-Q1: 4.43M shares2026-Q2: 3.18M shares
$20.24(+114.34%)
2026-06-30

About Siren L L Cโ€™s portfolio

Siren L L C reports $4.94B in US-listed equity holdings across 115 positions in its most recent 13F filing. Its largest disclosed positions are SRRK (10.7%), KYMR (6.8%) and ERAS (4.2%). The top 20 holdings account for 62.17% of reported assets. Its disclosed equity book has returned +107.86% cumulatively over 7 quarters. Figures reflect the Q2 2026 filing.

Portfolio concentration

Portfolio concentration
SRRK โ€” 12.3% ($526.63M)KYMR โ€” 7.9% ($336.65M)ERAS โ€” 4.9% ($208.81M)MANE โ€” 4.8% ($203.51M)TNGX โ€” 4.5% ($193.17M)RVMD โ€” 3.9% ($168.55M)BCAX โ€” 3.9% ($166.35M)ARWR โ€” 3.3% ($139.83M)ONC โ€” 3.1% ($132.51M)EWTX โ€” 3.0% ($129.39M)Other โ€” 48.4% ($2.07B)
52%in top 10
  • SRRK12.3%
  • KYMR7.9%
  • ERAS4.9%
  • MANE4.8%
  • TNGX4.5%
  • RVMD3.9%
  • BCAX3.9%
  • ARWR3.3%
  • ONC3.1%
  • EWTX3.0%
  • Other48.4%

Portfolio changes

What the fund actually did

Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.

New buys
5
ABVXAbivax SA1.6%
RLAYRelay Therapeutics Inc1.4%
COFCapital One Finl Corp0.7%
ORKAOruka Therapeutics Inc0.5%
+1 opened
Added to
19
ELVNEnliven Therapeutics Inc+137.8%
RYTMRhythm Pharmaceuticals Inc+56.6%
DFTXDefinium Therapeutics Inc+54.4%
MANEVeradermics Inc+10.0%
+15 more
Trimmed
12
SRRKScholar Rock Holding Corp-11.5%
EWTXEdgewise Therapeutics Inc-28.1%
RVMDRevolution Medicines Inc-19.0%
KYMRKymera Therapeutics Inc-7.9%
+8 more

Unlock alerts, watchlists & AI chat

Sign up free to track Siren L L C, compare funds side by side, and get alerts the moment positions change.

Source filings

Holdings on this page are parsed from Siren L L Cโ€™s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 2005245). View Siren L L Cโ€™s 13F filings on SEC

More 13F analyses

View all